ACR325 also belongs to the class of dopaminergic stabilisers and has been granted the INN name "ordopidine".
NeuroSearch is completing a Phase Ib tolerability study which is being conducted with the aim of evaluating the safety profile of ordopidine in Parkinson patients with L-Dopa-induced dyskinesias. In parallel, NeuroSearch has initiated the planning and preparation of a Phase II efficacy study with ordopidine within the same indication, and the study is expected to start in the first half of 2011.
